Solana (HSDT) & Its Rivals Head-To-Head Comparison

Solana (NASDAQ:HSDT) is one of 342 publicly-traded companies in the “Financial Services” industry, but how does it compare to its rivals? We will compare Solana to related businesses based on the strength of its profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Analyst Ratings

This is a breakdown of current recommendations for Solana and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1	1	2	0	2.25
Solana Competitors	1970	6870	11619	443	2.50

Solana currently has a consensus target price of $4.00, suggesting a potential upside of 91.39%. As a group, “Financial Services” companies have a potential downside of 1.58%. Given Solana’s higher possible upside, analysts plainly believe Solana is more favorable than its rivals.

Volatility and Risk

Solana has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Solana’s rivals have a beta of 2.49, meaning that their average share price is 149% more volatile than the S&P 500.

Valuation & Earnings

This table compares Solana and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Solana	$12.07 million	-$40.89 million	-0.07
Solana Competitors	$24.41 billion	$1.07 billion	8.38

Solana’s rivals have higher revenue and earnings than Solana. Solana is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Solana and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Solana	-1,302.78%	-41.86%	-18.53%
Solana Competitors	-409.62%	-15.98%	-6.09%

Insider and Institutional Ownership

18.6% of Solana shares are owned by institutional investors. Comparatively, 43.0% of shares of all “Financial Services” companies are owned by institutional investors. 14.4% of Solana shares are owned by insiders. Comparatively, 21.9% of shares of all “Financial Services” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Solana rivals beat Solana on 12 of the 13 factors compared.

Solana Company Profile

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.